MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
Rhea-AI Summary
MindMaze Therapeutics (RLFTF) announced on March 19, 2026 that Baader Bank has initiated equity research coverage with a Buy recommendation and a CHF 1.80 target price.
According to the company, this new coverage complements existing research from Edison Group, which values the company at CHF 3.56 per share.
Positive
- Baader Bank initiated coverage with a Buy recommendation
- New analyst coverage may increase visibility and liquidity for RLFTF shares
Negative
- Target price divergence: Baader CHF 1.80 vs Edison CHF 3.56
Key Figures
Market Reality Check
Peers on Argus
RLFTY fell 34.4% while key biotechnology peers were mixed: RLFTF up 3.17%, CVALF up 1.93%, POLBF and SEOVF flat, and ZIVO down 0.85%. With no peers in the momentum scanner and moves not broadly aligned, trading appeared stock-specific rather than sector-driven ahead of this new coverage.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Reimbursement strategy | Positive | +12.6% | Global reimbursement push and Swiss-backed flagship program announcement. |
| Dec 15 | Business combination close | Neutral | -61.3% | Completion of NeuroX combination and listing as MindMaze Therapeutics. |
| Nov 14 | Deal approval | Positive | -7.3% | Shareholder approval of NeuroX business combination and capital increase. |
| Oct 29 | Clinical study result | Positive | +0.2% | Pivotal bioequivalence study success for RLF-OD032 vs KUVAN Powder. |
News has produced mixed reactions: strategic and clinical positives sometimes aligned with gains but large structural changes saw sharp drawdowns.
Over the last few months, the company moved through major strategic and clinical milestones. On Oct 29, 2025, positive pivotal bioequivalence data for RLF-OD032 led to a modest 0.16% gain. Shareholders approved the NeuroX combination on Nov 14, 2025, yet the stock fell 7.3%. Completion of the business combination on Dec 15, 2025 coincided with a sharp 61.34% drop after issuing 140,000,000 new shares. A global reimbursement strategy update on Dec 23, 2025 then saw a positive 12.57% reaction. Today’s new analyst coverage comes against this backdrop of volatile responses to corporate developments.
Market Pulse Summary
This announcement adds another supportive data point, with Baader Bank initiating coverage with a Buy rating and CHF 1.80 target, complementing Edison’s CHF 3.56 valuation. It follows a period of major change, including a business combination that increased the share count to 152,602,044 and coincided with a 61.34% decline. Earlier, positive clinical results and a reimbursement-focused Swiss program of CHF 11.2 million underpinned the growth narrative. Investors may monitor how future clinical, reimbursement, and integration milestones influence sentiment relative to these benchmarks.
AI-generated analysis. Not financial advice.
GENEVAD, SE / ACCESS Newswire / March 19, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company's shares.
Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF 1.80 per share. This new coverage complements the existing research coverage provided by Edison Group, which currently values the Company at CHF 3.56 per share.
About MindMaze Therapeutics
MindMaze Therapeutics (SIX:MMTX) is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The Company's FDA-cleared and CE-marked neurotherapeutics are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.
For more information, visit www.mindmazetherapeutics.com.
Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com
Media Inquiries:
VSC for MindMaze Therapeutics
mindmazetherapeutics@vsc.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company's ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: MindMaze Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
What did MindMaze Therapeutics (RLFTF) announce on March 19, 2026?
What is Baader Bank's recommendation and target price for RLFTF?
How does Baader Bank's CHF 1.80 target compare to Edison's valuation for RLFTF?
Could Baader Bank's coverage affect MindMaze Therapeutics (RLFTF) stock trading?
Does the announcement change MindMaze Therapeutics' guidance or financials for RLFTF?
